Compare CINT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CINT | AQST |
|---|---|---|
| Founded | 1995 | 2004 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.2M | 529.4M |
| IPO Year | 2021 | 2007 |
| Metric | CINT | AQST |
|---|---|---|
| Price | $3.01 | $4.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $7.35 | ★ $9.00 |
| AVG Volume (30 Days) | 89.3K | ★ 2.4M |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | $16.69 | $10.08 |
| Revenue Next Year | $11.28 | $49.60 |
| P/E Ratio | $17.94 | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $2.80 | $2.94 |
| 52 Week High | $6.06 | $7.55 |
| Indicator | CINT | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 41.08 | 54.82 |
| Support Level | $2.80 | $4.03 |
| Resistance Level | $3.62 | $5.10 |
| Average True Range (ATR) | 0.18 | 0.24 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 34.71 | 45.13 |
CI&T Inc operates as a partner in tech-integrated business solutions, helping organizations address complex challenges by integrating business approach, technology, and artificial intelligence into a single, coherent operating model. It is mainly engaged in the development of customizable software through the implementation of software solutions, including machine learning, artificial intelligence, data analytics, cloud migration and mobility technologies. The company provides technology services to various industry verticals, including Financial Services, Consumer Goods, Technology and Communications, Retail and Industrial Goods, Life Sciences, among others. The majority of the revenue is derived from providing technology services. Geographically, maximum revenue is derived from Brazil.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.